Inotiv, Inc.

OTCPK:NOTV.Q Stock Report

Market Cap: US$1.7m

Inotiv Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Inotiv.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth17.0%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Narrative Update • Jun 03

NOTV: Future P/E And Margins Will Drive Upside Despite Bankruptcy

Analysts have updated their view on Inotiv with a revised $5.00 price target, citing refreshed assumptions for revenue growth, profit margins, discount rate, and future P/E, which collectively adjust the stock's risk and return profile without changing the headline valuation level. What's in the News Inotiv and multiple affiliates filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on June 3, 2026, with reported assets and liabilities each in the range of US$500m to US$1b.
Narrative Update • May 15

NOTV: Improving Margins And Higher Future P/E Will Support Upside

Analysts have held their fair value estimate for Inotiv steady at $3.25, citing updated assumptions for revenue growth of 5.99%, a profit margin of 15.62%, a discount rate of 12.46% and a future P/E of 1.76x as key inputs behind the maintained target. Valuation Changes Fair Value: Held steady at $3.25, with no change in the model output.
Narrative Update • Apr 29

NOTV: Refined Outlook Will Rely On Margin Execution And Future P/E

Narrative Update on Inotiv Analysts reduced their price target on Inotiv by $1.50, aligning the change with updated expectations for slightly different revenue growth, profit margin, and future P/E assumptions. Analyst Commentary The latest move to trim the price target by $1.50 reflects analysts fine tuning their models for Inotiv, with updated assumptions around revenue mix, profitability, and future P/E levels.
Narrative Update • Apr 15

NOTV: Margin Execution And Higher Future P/E Will Support Upside

Analysts have trimmed their price target on Inotiv by $1.50 to reflect updated expectations for profit margins and a slightly higher assumed future P/E multiple. Analyst Commentary Recent research suggests that the trimmed price target reflects a recalibration of expectations rather than a complete shift in the investment case for Inotiv.
Narrative Update • Apr 01

NOTV: Future Upside Will Depend On Meeting Nasdaq Bid Price Requirement

Analysts have lowered their price target on Inotiv by $1.50 to reflect updated fair value estimates, a slightly adjusted discount rate, and modest changes to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Bearish analysts lowering the price target by $1.50 are signaling a more cautious stance on how Inotiv is priced relative to updated fair value estimates.
Narrative Update • Mar 18

NOTV: Refined Outlook Will Rely On Margin Execution And Nasdaq Compliance

Analysts have reduced their price target on Inotiv by $1.50, citing updated assumptions about slightly different revenue growth, profit margin and future P/E expectations, while maintaining their fair value estimate of $5.00. Analyst Commentary Even with the reduced price target, bullish analysts continue to see a path where the current fair value estimate of $5.00 is supported by Inotiv's revenue profile, margin potential and P/E framework.
Narrative Update • Mar 06

The Global Shortage of Research Primates and Why It May Matter for Inotiv

Non-human primates (NHPs), particularly cynomolgus macaques, remain one of the most important animal models in modern drug development. Their physiological similarity to humans makes them essential for evaluating safety, pharmacokinetics, and toxicity before new drugs enter human clinical trials.
Narrative Update • Mar 04

The Hidden Scientific Infrastructure Behind Inotiv.

Introduction In recent years, Inotiv has frequently appeared in the news due to a series of challenges. These include regulatory issues related to the Envigo acquisition, global disruptions in non-human primate supply chains, debt inherited through acquisitions, and even a cybersecurity incident.
Narrative Update • Mar 04

NOTV: AI Data Partnership Will Support Future Upside Despite Going Concern Risk

Analysts have reduced their price target on Inotiv by $1.58 to $3.25, citing updated assumptions around fair value, the discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Analysts cutting their target price to US$3.25 are essentially saying their expectations around Inotiv’s execution, growth profile, and risk level have shifted.
Narrative Update • Feb 23

Why March 6 and March 31 Matter

— In Light of Inotiv, Inc.’s Eighth Amendment and Recent Institutional Disclosure In recent discussions surrounding Inotiv, Inc. (NASDAQ: NOTV), the dates of March 6 and March 31 have been frequently highlighted as important milestones.
Narrative Update • Feb 17

NOTV: Recalibrated Outlook Will Rely On Execution And AI Collaboration

Analysts have reduced their price target for Inotiv by $4.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, which reflect a more cautious but still constructive view on the company. Analyst Commentary Bullish analysts are framing the lower price target as a recalibration of assumptions rather than a loss of confidence in Inotiv.
Narrative Update • Feb 13

Inotiv's Margin Discipline Will Reshape Its Financial Future

Inotiv does not need perfection. It needs margin discipline.
New Narrative • Feb 11

Inotiv NAMs Test Center

Dear Inotiv, My name is Jong Ik Kwon, DVM , a graduate of Seoul National University College of Veterinary Medicine. Earlier in my career, I worked for Kwangdong Pharmaceutical as a Clinical Research Manager (CRM) for two years , where I gained direct experience in clinical development, regulatory processes, and pharmaceutical operations.
Narrative Update • Feb 03

NOTV: Raised Fair Value Will Rely On AI Collaboration Execution

Analysts have raised their fair value estimate for Inotiv from $2.50 to $3.00, citing updated assumptions on revenue growth, profit margins and future P/E, even as they apply a slightly higher 12.5% discount rate. What's in the News On December 31, 2025, Inotiv received a Nasdaq notification that its common stock did not meet the Minimum Bid Price Rule of a US$1.00 closing bid for 30 consecutive business days, starting a 180 day window, to June 29, 2026, to regain compliance under Listing Rule 5550(a)(2) (Nasdaq notice).
Narrative Update • Jan 20

NOTV: AI Data Collaboration Will Drive Upside Despite Going Concern Risk

Analysts have kept their Inotiv price target broadly steady, adjusting their fair value estimate to US$4.83. Small tweaks to profit margin and future P/E assumptions left their overall view largely unchanged.
Narrative Update • Jan 06

NOTV: AI Collaboration And Margin Expansion Will Support Upside Despite Going Concern Risk

Analysts have kept their price target for Inotiv steady at US$4.83, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Inotiv and VUGENE announced a collaboration to integrate VUGENE's cloud-based bioinformatics and computational platform into Inotiv's Discovery & Translational Sciences Division, aimed at more efficient analysis of complex biological data across epigenomic, proteomic, and other molecular datasets (Key Developments).
Narrative Update • Dec 19

NOTV: Future Margin Improvements Will Support Upside Despite Going Concern Risk

Narrative Update on Inotiv Analysts have modestly raised their price target on Inotiv to approximately $4.83 per share, citing slightly improved long term profit margin expectations and a marginally more attractive future earnings multiple. What's in the News Auditor Ernst & Young issued an unqualified opinion on Inotiv's latest 10 K but raised substantial doubt about the company’s ability to continue as a going concern, highlighting liquidity and sustainability risks for investors (10 K filing).
Narrative Update • Dec 05

NOTV: Future Margins And Legal Settlement Will Support Share Upside

Narrative Update on Inotiv Analysts have lowered their average price target on Inotiv by roughly 12 percent, to about $4.83 per share from around $5.50. They cite slightly softer revenue growth assumptions that are only partly offset by expectations for improved profit margins and a lower future earnings multiple.
Analysis Article • Jun 27

Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 28% Share Price Slump

Inotiv, Inc. ( NASDAQ:NOTV ) shareholders won't be pleased to see that the share price has had a very rough month...
Analysis Article • May 03

Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 29% Share Price Slump

Unfortunately for some shareholders, the Inotiv, Inc. ( NASDAQ:NOTV ) share price has dived 29% in the last thirty...
Analysis Article • Apr 25

Health Check: How Prudently Does Inotiv (NASDAQ:NOTV) Use Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
User avatar
New Narrative • Apr 06

NHP Facilities And North American Optimization Will Secure Stability

Expanding the non-human primates client base and investments in facilities aim to stabilize revenue and enhance profitability through improved service offerings.
Analysis Article • Mar 11

Market Cool On Inotiv, Inc.'s (NASDAQ:NOTV) Revenues Pushing Shares 32% Lower

To the annoyance of some shareholders, Inotiv, Inc. ( NASDAQ:NOTV ) shares are down a considerable 32% in the last...
Analysis Article • Dec 06

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article • Apr 26

Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues

The Inotiv, Inc. ( NASDAQ:NOTV ) share price has softened a substantial 57% over the previous 30 days, handing back...
Analysis Article • Mar 19

Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Feb 13

Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Inotiv, Inc. ( NASDAQ:NOTV ) shares have continued their recent momentum with a 34% gain in the last month alone...
Analysis Article • Dec 18

Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company

Those holding Inotiv, Inc. ( NASDAQ:NOTV ) shares would be relieved that the share price has rebounded 61% in the last...
Analysis Article • Dec 13

Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81

It's been a sad week for Inotiv, Inc. ( NASDAQ:NOTV ), who've watched their investment drop 19% to US$2.55 in the week...
Analysis Article • Nov 21

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Aug 14

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Inotiv has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:NOTV.Q - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2026507-87-140N/A
12/31/2025514-69-29-11N/A
9/30/2025513-69-27-10N/A
6/30/2025505-79-46-27N/A
3/31/2025480-87-54-34N/A
12/31/2024475-121-26-5N/A
9/30/2024491-108-29-7N/A
6/30/2024501-99-914N/A
3/31/2024553-711033N/A
12/31/2023585-33429N/A
9/30/2023572-105028N/A
6/30/2023582-340-179N/A
3/31/2023597-345-42-4N/A
12/31/2022586-341-50-11N/A
9/30/2022548-337-42-5N/A
6/30/2022427-83-38-3N/A
3/31/2022277-77-1510N/A
12/31/2021156-72-98N/A
9/30/20219011-211N/A
6/30/2021750-28N/A
3/31/202168-405N/A
12/31/202065-4-41N/A
9/30/202060-5-51N/A
6/30/202059-3-62N/A
3/31/202055-2-71N/A
12/31/201948-2N/A2N/A
9/30/201944-1N/A2N/A
6/30/201938-1N/A3N/A
3/31/201933-1N/A4N/A
12/31/2018300N/A4N/A
9/30/2018260N/A3N/A
6/30/2018230N/A2N/A
3/31/2018231N/A2N/A
12/31/2017231N/A1N/A
9/30/2017241N/A1N/A
6/30/201724-1N/A2N/A
3/31/201723-2N/A1N/A
12/31/201622-3N/A2N/A
9/30/201620-3N/A1N/A
6/30/201620-2N/A1N/A
3/31/2016210N/A2N/A
12/31/2015220N/A2N/A
9/30/2015231N/A2N/A
6/30/2015241N/A2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NOTV.Q's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if NOTV.Q's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if NOTV.Q's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NOTV.Q's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if NOTV.Q's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NOTV.Q's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 17:50
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inotiv, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew HewittCraig-Hallum Capital Group LLC
David WindleyJefferies LLC
Jeffrey CohenLadenburg Thalmann & Company